Our results suggest that prospective clinical studies including a quantitative evaluation of full-length HER2 and Delta16 could improve the prediction of breast cancer sensitivity and resistance to cytotoxic and HER2 targeted therapies. Here, ERBB2 is linked to breast carcinoma.